Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

"This study allowed us to do a direct comparison ... "Across the respective clinical trial programs and in SURMOUNT-5, both Wegovy and Zepbound have demonstrated clinically significant weight ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...